| The incidence of BCR-ABL fusion oncogene in Pakistani patients with childhood acute lymphoid leukemia is diferent from other populations. | leukemia, |
| Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. | lung, |
| Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia. | leukemia, |
| Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation. | leukemia, |
| Leukemia initiated by hemopoietic stem cells expressing the v-abl oncogene. | leukemia, |
| ABL oncogene expression during erythroleukemia cell differentiation. | leukemia, |
| BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. | leukemia, |
| Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer. | breast, |
| Overexpression of c-ABL proto-oncogene is associated with enhanced resistance to tamoxifen in breast cancer. | breast, |
| A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes. | neoplasm, |
| Bcr-Abl stability and oncogenic signaling in chronic myeloid leukemia (CML) cells are under the control of Jak2. | leukemia, |
| Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells. | leukemia, |
| Overcoming resistance to fulvestrant (ICI182,780) by downregulating the c-ABL proto-oncogene in breast cancer. | breast, |
| Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of beta-catenin and STAT1 in chronic myeloid leukemia cells. | leukemia, |
| Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. | leukemia, |
| The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia. | leukemia, |
| report of rare, concomitant occurrence of Janus kinase 2 V617F mutation with BCR-ABL (breakpoint cluster region--c-abl oncogene 1 fusion protein) translocation at presentation in five patients with atypical myeloproliferative neoplasm [CASE REPORT] | neoplasm, |
| Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis. | neoplasm, |
| Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib. | leukemia, |
| Rearrangement of the human ABL oncogene in a glioblastoma. | glioblastoma, |